By the end of 2024, 30% of global clinical trials will come from China, and the development rate in the biopharmaceutical field in China far exceeds that of the past.

On May 23rd, Cynthia L. VERST, President of Research and Development Solutions Design and Delivery Innovation at IQVIA, stated at the Zhangjiang Technology and Innovation Salon Global Innovation Leaders session that by the end of 2024, 30% of clinical trials will be conducted in China, 35% in the United States, and a small percentage in Europe. The 30% in China is a significant increase, and it continues to grow every year. We see that China's development rate globally far exceeds the past.